Trial: 202011174

Tazemetostat and Pembrolizumab in Patients with Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial

Phase

I/II

Principal Investigator

Adkins, Douglas

Disease Site

Larynx; Lip, Oral Cavity and Pharynx

Learn more about this study at: clinicaltrials.gov